H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Vertex Pharmaceuticals to $390 from $380 and keeps a Buy rating on the shares. Given that Vertex has completed the diabetic peripheral neuropathy Phase 2 study, and the announcement that the company plans to initiate trial focused on lumbosacral radiculopathy, indicates that company remains positive about VX-548’s mechanism of action, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $408 from $399 at Barclays
- Vertex raises FY23 CF product revenue view to about $9.85B
- Vertex Pharmaceuticals reports Q3 EPS $3.98, consensus $3.97
- Fly Insider: Barnes Group, Palo Alto among week’s notable insider trades
- Notable companies reporting after market close